The aim of this study was to establish whether the HER2 status and KRAS status of primary tumors reflect that of their associated metastases and thus whether decisions to treat metastatic disease with anti-HER2 agents can be based on the assessment of the primary tumors. Here, ERBB2 is linked to metastatic neoplasm.